Daiichi and AstraZeneca claim another breast cancer success, and further evidence of the ADC’s activity in very low HER2 expression.

Abstract titles reveal some of ASCO’s key datasets.

Amid doubts about early data with FG-3246, the group is scathing about its rivals.

More efficient internalisation and release – not bystander activity – are the focus for this private ADC player.

An analysis of OncologyPipeline shows that $144bn has been pledged for ADCs since the start of 2022.

The company looks rash for promising Tamarack data at the conference, although at least vobra duo’s safety has improved.

Genmab’s remarkably bold acquisition raises more questions about Sutro, a key FRα rival of ProfoundBio.